[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100450190":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":60,"collaborators":62,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Adults with chronic non-cancer low back pain",null,[12,13,14],"Drug: Placebo","Drug: Oxycodone","Drug: Naloxone",[16,23,26],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Placebo","In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg\u002Fkg of oral oxycodone (in 1mg\u002Fml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).\n\nThermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.",[9],[22],"normal saline placebo",{"type":17,"name":24,"description":19,"armGroupLabels":25,"otherNames":10},"Oxycodone",[9],{"type":17,"name":27,"description":19,"armGroupLabels":28,"otherNames":29},"Naloxone",[9],[30],"narcan",[32],{"name":33,"affiliation":5,"role":34},"Stephen Bruehl, PhD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":10,"email":39},"CONTACT","615-936-1821","stephen.bruehl@vumc.org",{"name":41,"role":37,"phone":42,"phoneExt":10,"email":43},"Gail Mayo","615-936-1705","gail.mayo@vumc.org",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Nashville","Tennessee","37212","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-86.78444,36.16589,{"lat":56,"lon":55},[59],{"name":33,"role":37,"phone":10,"phoneExt":10,"email":10},{"type":34,"investigatorFullName":33,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Professor of Anesthesiology",[63],{"name":64,"class":65},"National Institute on Drug Abuse (NIDA)","NIH","100450190","stress-and-opioid-misuse-risk-the-role-of-endogenous-opioid-and-endocannabinoid-mechanisms-100450190",false,"NCT05142267","Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms","Inclusion Criteria:\n\n* Intact cognitive status and ability to provide informed consent\n* Ability to read and write in English sufficiently to understand and complete study questionnaires (which are only validated in English)\n* Age 18 or older And\n* Presence of persistent daily low back pain of at least three months duration and of at least a 3\u002F10 in average intensity\n\nExclusion Criteria:\n\n* History of renal or hepatic dysfunction\n* Reports of current or past alcohol or substance abuse or treatment for such condition\n* A reported history of PTSD, psychotic, or bipolar disorders\n* Chronic pain due to malignancy (e.g., cancer) or autoimmune disorders (e.g., rheumatoid arthritis, lupus)\n* Reports of recent benzodiazepine use (confirmed via rapid urine screening prior to each lab session)\n* Any medical conditions (e.g., significant cardiovascular disease) that the study physician feels would contraindicate participation in the lab stressors\n* Reported daily opiate use within the past 6 months, or use of any opioid analgesic medications within 3 days of study participation (confirmed through rapid urine screening prior to each lab session)\n* Pregnancy (females only, to avoid fetal drug exposure - pregnancy tests conducted prior to each lab session to confirm eligibility)\n* Prior allergic reaction\u002Fintolerance to oxycodone or its analogs","ALL","18 Years",{"count":75,"type":76},120,"ESTIMATED","INTERVENTIONAL",[79],"NA","The purpose of this study is to see how stress influences the effects of opioid pain medications often used to help relieve back pain. The study will help to learn more about how high stress levels could increase risk for pain medication misuse.",[82,83,84],"Opioid Use Disorder","Back Pain","Stress","2025-10-20",{"date":87,"type":88},"2025-10-21","ACTUAL",{"date":90,"type":88},"2022-03-02",{"date":92,"type":76},"2026-07-31",{"name":5,"class":6},1]